Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-135.00K | 0.00 | -571.00K | -1.81M | -685.00K | -209.00K | EBIT |
-31.16M | -32.61M | -37.06M | -50.19M | -37.48M | -19.45M | EBITDA |
-28.77M | -32.61M | -33.39M | -46.56M | -36.80M | -18.50M | Net Income Common Stockholders |
-29.03M | -30.16M | -34.10M | -48.81M | -37.46M | -20.63M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
34.33M | 41.34M | 65.76M | 17.80M | 147.62M | 16.60M | Total Assets |
38.27M | 45.36M | 74.37M | 118.38M | 153.22M | 21.43M | Total Debt |
3.21M | 3.85M | 6.21M | 8.03M | 2.35M | 567.00K | Net Debt |
-6.67M | -6.15M | -6.80M | -9.76M | -4.80M | -16.03M | Total Liabilities |
6.29M | 6.97M | 9.48M | 14.97M | 6.71M | 77.87M | Stockholders Equity |
31.99M | 38.39M | 64.89M | 103.41M | 146.51M | -56.44M |
Cash Flow | Free Cash Flow | ||||
-24.26M | -24.82M | -32.20M | -39.35M | -32.28M | -18.91M | Operating Cash Flow |
-24.15M | -24.67M | -32.02M | -39.03M | -30.26M | -17.70M | Investing Cash Flow |
23.86M | 22.44M | 38.41M | 49.95M | -143.12M | -1.40M | Financing Cash Flow |
-792.00K | -787.00K | -11.17M | -287.00K | 163.94K | 35.45M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $5.25B | 3.27 | -44.35% | 6.27% | 16.79% | -0.10% | |
51 Neutral | $3.37M | ― | -205.75% | ― | 2552.29% | 60.70% | |
49 Neutral | $15.80M | ― | -92.35% | ― | -85.48% | 45.13% | |
45 Neutral | $3.19M | ― | -468.00% | ― | ― | 98.55% | |
41 Neutral | $23.50M | ― | -160.26% | ― | ― | 19.21% | |
40 Underperform | $164.36M | ― | -64.18% | ― | ― | 1.00% | |
36 Underperform | $12.51M | ― | -110.70% | ― | ― | 18.61% |
On March 27, 2025, Sensei Biotherapeutics announced favorable preliminary results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a monoclonal antibody targeting VISTA, in PD-(L)1 resistant tumors. The trial showed an overall response rate nearly three times higher than historical PD-(L)1 rechallenge rates, with notable responses observed in Merkel Cell Carcinoma and MSI-H Colorectal Cancer patients. These findings suggest solnerstotug may offer a significant clinical benefit in select tumor types. The company plans to initiate a Phase 2 study in early 2026, contingent on securing sufficient capital, with ongoing analyses to optimize trial design and patient selection.